Clinical Trial Update: Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic and safety study of VX-770 (ivacaftor) in subjects with moderate hepatic impairment and matched healthy controls has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Kalydeco (ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: In Development for Cystic Fibrosis | Phase 1 | Status: COMPLETED